What is the primary treatment approach for chronic lymphocytic leukemia (CLL)?

The primary treatment approach for chronic lymphocytic leukemia (CLL) is often active surveillance, also known as watchful waiting. This strategy is utilized particularly in patients who are asymptomatic or have early-stage CLL. The rationale behind active surveillance is that CLL progresses slowly in many patients, and immediate treatment may not be necessary. By monitoring the patient's condition over time, healthcare providers can initiate treatment only when there is evidence of disease progression or the development of symptoms.

In cases where the disease begins to show signs of progression, or if the patient starts experiencing symptoms, more aggressive treatments like chemotherapy or targeted therapies can then be considered. Therefore, utilizing active surveillance in the initial stages of CLL allows patients to maintain a good quality of life while minimizing the potential side effects associated with more intensive treatments when they are not yet needed.